SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Advances Cancer Trials, Is It A Bargain?
Shanghai Henlius Biotech (SEHK:2696) is back in focus after Chinese regulators cleared phase 1 trials for its HLX37 combination therapies, while a separate study for bispecific ADC HLX48 has already started dosing patients.
See our latest analysis for Shanghai Henlius Biotech.
The latest HLX37 and HLX48 updates come after a mixed stretch for Shanghai Henlius Biotech, with the share price up 9.77% over 30 days but down 24.54% over 90 days, while the 1 year and 3 year total shareholder returns...